Hemoglobin fluorescent probe as well as preparation method and application thereof
By designing a high sensitivity and high signal-to-noise ratio hemoglobin fluorescent probe, using metabolic processes or competitive substitution of non-steroidal anti-inflammatory drugs, the controllable dissociation between the probe and hemoglobin is solved, and the existing probes are complex The problems of stability and accuracy in the environment achieve real-time and accurate monitoring of hemoglobin concentration and early diagnosis of disease.
Patent Information
- Application Number
- CN202411135246.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-19
AI Technical Summary
There is room for improvement in the sensitivity and selectivity of existing hemoglobin fluorescent probes, especially in complex physiological environments, which are difficult to maintain stability and accuracy, especially when patients take drugs that have strong plasma protein binding capabilities.
A hemoglobin fluorescent probe with high sensitivity and high signal-to-noise ratio was designed to achieve controllable dissociation between the probe and hemoglobin through specific metabolic processes or competitive substitution of non-steroidal anti-inflammatory drugs and probes. It has strong near-infrared fluorescence characteristics, is significantly quenched only when bound to hemoglobin, and is effectively resistant to interference from multiple drugs.
Real-time and accurate monitoring of hemoglobin concentration is achieved, with high response sensitivity and anti-interference ability, and is suitable for hemoglobin-mediated controllable biological imaging, providing more accurate and timely disease diagnosis information.
Smart Images

Figure CN119039218A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of fluorescent probes, and in particular relates to a hemoglobin fluorescent probe and a preparation method and application thereof. Background Art
[0002] Hemoglobin is the main protein of red blood cells. Abnormal hemoglobin concentration is associated with a variety of diseases, such as anemia, liver disease, kidney disease, malignant tumors, etc. In-depth study of its structure and function is crucial to understanding life processes and disease mechanisms. Therefore, a deep understanding of the structure and function of hemoglobin is of great significance for revealing the mysteries of life processes and the mechanisms of disease occurrence. Bovine hemoglobin and human hemoglobin have extremely high similarities in structure and spectral properties. Because bovine hemoglobin is easier to obtain, it is often used as a hemoglobin model for various spectral studies and mechanism analyses. At present, although there are many methods for the detection of hemoglobin, such as electrophoresis, chromatography and colorimetry, most of these methods can only be performed in a laboratory environment, and often cannot achieve real-time dynamic monitoring of hemoglobin concentration.
[0003] Fluorescent probes, with their unique optical properties, such as high sensitivity, high selectivity, rapid response, and visual imaging, provide new possibilities for real-time monitoring of hemoglobin. By designing and synthesizing specific fluorescent probes for hemoglobin, real-time, in-situ, and non-invasive monitoring of hemoglobin concentration can be achieved, providing more accurate and timely information for early diagnosis and treatment of diseases. Although there have been some reports on the research of hemoglobin fluorescent probes, there is still significant room for improvement in the sensitivity and selectivity of existing probes. Especially in complex physiological environments, such as when patients take drugs with strong plasma protein binding ability, these probes face challenges in maintaining their stability and accuracy. Therefore, it is of great significance to develop new hemoglobin fluorescent probes with higher sensitivity and selectivity to promote the development of hemoglobin monitoring technology. Summary of the invention
[0004] In view of the problems existing in the hemoglobin detection in the prior art, the present invention provides a hemoglobin fluorescent probe with high sensitivity, high signal-to-noise ratio and controllable fluorescence signal, which can realize in vitro hemoglobin detection or hemoglobin-mediated precise and controllable intracellular fluorescence imaging.
[0005] To achieve the above object, the present invention first provides a hemoglobin fluorescent probe, characterized in that it has the following structural formula:
[0006]
[0007] The fluorescent probe of the present invention can provide a low background fluorescence signal when binding to hemoglobin. Through a specific metabolic process or competitive substitution between non-steroidal anti-inflammatory drugs and the probe, the probe can be effectively dissociated from hemoglobin, and is suitable for hemoglobin-mediated controllable biological imaging, especially in monitoring the distribution and dynamic changes of hemoglobin in vivo. Compared with the prior art, the hemoglobin fluorescent probe of the present invention has the following advantages: (1) The hemoglobin fluorescent probe provided by the present invention has strong near-infrared fluorescence itself. When multiple proteins including hemoglobin are present, the probe fluorescence is significantly quenched only by hemoglobin, and has strong specificity;
[0008] (2) It has high response sensitivity, strong protein binding ability and anti-interference ability;
[0009] (3) The probe binds to hemoglobin through a non-covalent interaction. Through a specific metabolic process or the competitive substitution of the non-steroidal anti-inflammatory drug ibuprofen with the probe, the probe can be effectively dissociated from hemoglobin, thereby achieving a controllable fluorescence response of the probe to hemoglobin.
[0010] In order to further achieve the above-mentioned object of the present invention, the present invention also provides a method for preparing the above-mentioned hemoglobin fluorescent probe:
[0011] The steps include:
[0012] Step 1: Add 4-pyridineboronic acid, tetrakis(triphenylphosphine)palladium and K2CO3 to a mixture of 1,4-dioxane and H2O as solvents, then add 4′-(4-bromophenyl)acetophenone, stir and heat under reflux under nitrogen protection; after cooling, separate by column chromatography to obtain 4-(4-pyridyl)-biphenyl-4′-ethanone;
[0013] The synthesis process of this step is as follows:
[0014]
[0015] Step 2: dissolving the 4-(4-pyridyl)-biphenyl-4'-ethanone and malononitrile obtained in step 1 in toluene, adding ammonium acetate and acetic acid, stirring and heating under reflux, cooling and separating by column chromatography to obtain 2-isocyano-3-[4-(4-pyridyl)biphenyl-4'-yl]but-2-enenitrile;
[0016] The synthesis process of this step is as follows:
[0017]
[0018] Step 3: Potassium tert-butoxide and (formylmethylene)triphenylphosphine are stirred in a toluene solvent in an ice bath, added to 6-methoxy-2-naphthaldehyde, heated under reflux under nitrogen protection, cooled, and separated by column chromatography to obtain 3-(6-methoxynaphthalen-2-yl)acrolein;
[0019] The synthesis process of this step is as follows:
[0020]
[0021] Step 4: dissolving the 2-isocyano-3-[4-(4-pyridinyl)biphenyl-4'-yl]but-2-enenitrile obtained in the step, 3-(6-methoxynaphthalen-2-yl)acrolein obtained in step 3 and piperidine in dichloromethane, stirring and heating to reflux, cooling and separating by column chromatography to obtain 2-isocyano-7-(6-methoxynaphthalen-2-yl)-3-[4'-(pyridin-4-yl)biphenyl-4-yl]hept-2,4,6-trienenitrile;
[0022] The synthesis process of this step is as follows:
[0023]
[0024] Step 5: dissolving the 2-isocyano-7-(6-methoxynaphthalen-2-yl)-3-[4'-(pyridin-4-yl)biphenyl-4-yl]hept-2,4,6-trienenitrile and iodomethane obtained in step 4 in acetonitrile, stirring and heating under reflux, cooling and filtering, and eluting with anhydrous ether to obtain the hemoglobin fluorescent probe;
[0025] The synthesis process of this step is as follows:
[0026]
[0027] Furthermore, the specific process of step 1 is:
[0028] 1.1 Mix 4-pyridineboric acid, tetrakis(triphenylphosphine)palladium and K2CO3 with 1,4-dioxane and H2O, and stir to form a mixed solution; wherein,
[0029] 1.2 Dissolve 4′-(4-bromophenyl)acetophenone in 1,4-dioxane and mix with the mixed solution in step 1.1. Protect with nitrogen. Stir the mixed solution at 80°C for 8 hours. Monitor the reaction progress by TLC until the raw material 4′-(4-bromophenyl)acetophenone is completely consumed.
[0030] 1.3 After the reaction is completed, the mixture is cooled to room temperature, and the reactant is extracted three times with water and dichloromethane. The organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product is purified on a silica gel column to obtain 4-(4-pyridyl)-biphenyl-4'-ethanone;
[0031] In step 1, the molar ratio of 4-pyridineboric acid, tetrakis(triphenylphosphine)palladium, K2CO3 and 4′-(4-bromophenyl)acetophenone is 3:0.05:6:2; the volume ratio of 1,4-dioxane and H2O is 4:1, wherein the molar volume ratio of tetrakis(triphenylphosphine)palladium to 1,4-dioxane is 3.1-3.2 mmol / L.
[0032] The specific synthesis process of step 2 is:
[0033] 4-(4-pyridyl)-biphenyl-4'-ethanone and malononitrile were dissolved in toluene, and then ammonium acetate and acetic acid were added, and the mixture was refluxed for 12 hours. After the reaction was completed by TLC monitoring, the mixture was cooled to room temperature, and extracted with water and dichloromethane. After concentration under reduced pressure, the crude product was purified on a silica gel column to obtain 2-isocyano-3-[4-(4-pyridyl)biphenyl-4'-yl]but-2-enenitrile.
[0034] In this step, the molar ratio of 4-(4-pyridyl)-biphenyl-4'-ethanone, malononitrile, ammonium acetate and acetic acid is 14:15.4:4.62:13.02.
[0035] The specific synthesis process of step 3 is:
[0036] Potassium tert-butoxide and (formylmethylene)triphenylphosphine were stirred in toluene in an ice bath for 1 to 2 hours, then slowly dripped into 6-methoxy-2-naphthaldehyde and mixed, protected by nitrogen, reacted at 50°C for 24 hours, and after the reaction was completed, quenched with 30% dilute hydrochloric acid, then extracted with water and ethyl acetate, and after the solvent was evaporated, the crude product was purified on a silica gel column to obtain 3-(6-methoxynaphthalen-2-yl)propenal;
[0037] In this step, the molar ratio of 6-methoxy-2-naphthaldehyde, potassium tert-butoxide, and (formylmethylene)triphenylphosphine is 3:6:3.3.
[0038] The specific synthesis process of step 4 is:
[0039] 2-isocyano-3-[4-(4-pyridinyl)biphenyl-4'-yl]but-2-enenitrile and 3-(6-methoxynaphthalen-2-yl)acrolein in a molar ratio of 0.9:1 were mixed, dissolved in dichloromethane with piperidine, and refluxed for 6 to 8 hours. After concentration under reduced pressure, the crude product was purified on a silica gel column to obtain 2-isocyano-7-(6-methoxynaphthalen-2-yl)-3-[4'-(pyridin-4-yl)biphenyl-4-yl]hept-2,4,6-trienenitrile.
[0040] 2-Isocyano-7-(6-methoxynaphthalen-2-yl)-3-[4'-(pyridin-4-yl)biphenyl-4-yl]hept-2,4,6-trienenitrile and iodomethane 1 in a molar ratio of 0.43:1.3 were dissolved in acetonitrile and refluxed for 24 hours. After concentration under reduced pressure, acetonitrile was added until dissolved, precipitated with ether, filtered and washed to obtain the target hemoglobin fluorescent probe.
[0041] Furthermore, in the aforementioned steps, the silica gel column is a mixture of ethyl acetate and dichloromethane in a volume ratio of 1:2.
[0042] The present invention also provides an application of the above-mentioned hemoglobin fluorescent probe in hemoglobin detection or hemoglobin-mediated intracellular controllable fluorescence imaging. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0044] Figure 1 This is the hydrogen nuclear magnetic spectrum of the fluorescent probe of the present invention, and the solvent is d6-DMSO.
[0045] Figure 2 This is the nuclear magnetic carbon spectrum of the fluorescent probe of the present invention, and the solvent is d6-DMSO.
[0046] Figure 3 The comparison diagram of fluorescence intensity changes of fluorescent probes in different proteins (λ ex =520nm).
[0047] Figure 4 The fluorescence intensity of the fluorescent probe in different concentrations of bovine hemoglobin is compared (λ ex =520nm).
[0048] Figure 5 is the fluorescence quenching diagram of the fluorescent probe to bovine hemoglobin (λ ex =280nm).
[0049] Figure 6 This paper studies the effects of various common commercial drugs on the responsiveness of the fluorescent probe bovine hemoglobin.
[0050] Figure 7 The effect of different concentrations of ibuprofen on the response ability of the fluorescent probe bovine hemoglobin.
[0051] Figure 8These are the HepG2 cell toxicity test diagrams of the fluorescent probe and the complex of the fluorescent probe and bovine hemoglobin.
[0052] Fig. 9 Laser confocal fluorescence imaging of HepG2 cells stained with fluorescent probe, complex of fluorescent probe and bovine hemoglobin, and complex of fluorescent probe and bovine hemoglobin with ibuprofen added after 4h, 12h, and 24h respectively (λ ex =543nm). DETAILED DESCRIPTION
[0053] In order to enable those skilled in the art to better understand the technical solutions in the embodiments of the present invention and to make the above-mentioned objects, features and advantages of the present invention more obvious and understandable, the specific implementation modes of the present invention are further described below.
[0054] If the specific conditions are not specified in the examples, the experiments were carried out under conventional conditions or conditions recommended by the manufacturer. If the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be purchased commercially.
[0055] The embodiment of the present invention provides a protein structure-dependent hemoglobin fluorescent probe, the structural formula of which is:
[0056]
[0057] The synthetic route of the hemoglobin probe of the above structure is as follows:
[0058]
[0059] The present invention is further described below by way of examples.
[0060] Example 1 Preparation of hemoglobin fluorescent probe:
[0061] Step 1: Add 0.37g of 4-pyridineboronic acid 3mmol, 0.06g of tetrakis(triphenylphosphine)palladium 0.05mmol and 0.83g of K2CO3 6mmol to a 50mL Schlenk tube. Then add 16mL of 1,4-dioxane and 4mL of H2O. Then dissolve 0.55g of 4′-(4-bromophenyl)acetophenone 2mmol in 1,4-dioxane and add to the Schlenk tube. Under nitrogen protection, the mixture was stirred at 80°C for 8 hours, and the reaction progress was monitored by TLC. After the reaction was completed, it was cooled to room temperature, extracted with water and dichloromethane three times, the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified on a silica gel column (ethyl acetate / dichloromethane, 1 / 2, v / v) to obtain 4-(4-pyridyl)-biphenyl-4'-ethanone; its nuclear magnetic hydrogen spectrum parameters are: 1H NMR (400MHz, DMSO-d6) δ (ppm): 8.64 (s, 2H), 8.00 (d, J = 8.4Hz, 2H), 7.70 (s, 4H), 7.67 (d, J = 8.4Hz, 2H), 7.53 (d, J = 6.0Hz, 2H), 2.59 (s, 3H).
[0062] Step 2: Dissolve 0.39g 4-(4-pyridyl)-biphenyl-4'-ethanone 1.4mmol and 0.10g malononitrile 1.54mmol in 20mL toluene. Then add 0.35g ammonium acetate 4.62mmol and 0.74mL acetic acid 13.02mmol, and reflux for 12 hours. Monitor the reaction progress by TLC. After the reaction is completed, cool to room temperature and extract with water and dichloromethane. After concentration under reduced pressure, the crude product is purified on a silica gel column (ethyl acetate / petroleum ether, 2 / 1, v / v) to obtain 2-isocyano-3-[4-(4-pyridyl)biphenyl-4'-yl]but-2-enenitrile; its nuclear magnetic hydrogen spectrum parameters are: 1 H NMR (400MHz, CDCl3) δ (ppm): 8.67 (s, 2H), 8.00 (d, J = 8.4Hz, 2H), 7.70 (s, 4H), 7 .68(d,J=2.0Hz,1H),7.66(t,J=1.6Hz,1H),7.53(d,J=6.0Hz,2H),2.59(s,3H).
[0063] Step 3: Add 3 mmol of 0.69 g of 6-methoxy-2-naphthaldehyde to a Schlenk tube. Stir 6 mmol of 0.66 g of potassium tert-butoxide and 3.3 mmol of 0.99 g of (formylmethylene) triphenylphosphine in toluene in an ice bath for one to two hours and then slowly drop them into the Schlenk tube using a syringe. Protect with nitrogen and react at 50°C for 24 hours. After the reaction is completed, quench with 10 mL of 30% dilute hydrochloric acid. Then extract with water and ethyl acetate. After evaporation of the solvent, the crude product is purified on a silica gel column (ethyl acetate / petroleum ether, 1 / 1, v / v) to obtain 3-(6-methoxynaphthalene-2-yl) acrolein; its nuclear magnetic hydrogen spectrum parameters are: 1 H NMR (400MHz, CDCl3) δ (ppm): 9.73 (d, J = 7.6 Hz, 1H), 7.91 (s, 1H), 7.77 (t, J = 9.2 Hz,2H),7.66-7.58(m,2H),7.21-7.15(m,2H),6.82-6.76(m,1H),3.95(s,3H).
[0064] Step 4: 0.29 g of 2-isocyano-3-[4-(4-pyridinyl)biphenyl-4'-yl]but-2-enenitrile 0.9 mmol, 0.23 3-(6-methoxynaphthalen-2-yl)acrolein 0.99 mmol and 15 drops of piperidine were dissolved in 20 mL of dichloromethane and refluxed for 6 h. After concentration under reduced pressure, the crude product was purified on a silica gel column (ethyl acetate / petroleum ether, 2 / 1, v / v) to obtain 2-isocyano-7-(6-methoxynaphthalen-2-yl)-3-[4'-(pyridin-4-yl)biphenyl-4-yl]hept-2,4,6-trienenitrile; its H NMR spectrum parameters are: 1 H NMR (400MHz, CDCl3) δ (ppm): 8.67 (d, J = 5.2Hz, 2H), 8.11 (d, J = 8.0Hz, 2H), 7.92 (t, J = 11.6Hz, 3H) ,7.72(d,J=8.8Hz,7H),7.55(t,J=12.0Hz,4H),7.18(s,2H),7.10(d,J=8.8Hz,2H),3.88(s,3H).
[0065] 0.22 g of 2-isocyano-7-(6-methoxynaphthalen-2-yl)-3-[4'-(pyridin-4-yl)biphenyl-4-yl]hept-2,4,6-trienenitrile (0.43 mmol) and 0.18 g of iodomethane (1.3 mmol) were dissolved in 20 mL of acetonitrile and refluxed for 24 h. After concentration under reduced pressure, a small amount of acetonitrile was added to dissolve, precipitated with ether, filtered and washed to obtain the target probe; its H NMR spectrum parameters are: 1 H NMR (400MHz, DMSO-d6) δ (ppm): 9.04 (d, J = 6.8 Hz, 2H), 8.61 (d, J = 6.8 Hz, 2H), 8.28 (t, J = 14.4 Hz, 2H), 8.18-8.07 (m, 4H), 7.96-7.73 (m, 4H), 7.71-7.46 (m, 3H), 7.40-7.26 (m, 2H), 7.22-7.01 (m, 2H), 6.96-6.87 (m, 1H), 4.36 (s, 3H), 3.90-3.79 (m, 3H). Its carbon NMR spectrum parameters are: 13 C NMR(101MHz,DMSO-d6)δ(ppm):170.4,170.3,159.8,153.3,149.9,146.3,143.6,137.0,136.7,136.6,136.2,132.6,131 .1,130.8,129.9,129.1,129.0,128.6,128.4,125.0,124.7,124.6,123.4,120.1,114.5,113.6,106.9,81.4,56.0,47.8.
[0066] Figure 1 This is the H NMR spectrum of the hemoglobin probe synthesized in the above embodiment of the present invention, the solvent is d6-DMSO; Figure 2 This is the nuclear magnetic carbon spectrum of the fluorescent probe of the present invention, and the solvent is d6-DMSO.
[0067] Example 2 Fluorescent probe protein selective response test:
[0068] Preparation of mother solution: The probe was dissolved in DMSO, hemin was dissolved in acidic acetone, and the concentration was 2 mM. Pepsin was dissolved in 0.1 M phosphate buffered saline (PBS) with a pH of 2.0, and bovine hemoglobin, trypsin, lysozyme, α-chymotrypsin, and γ-globulin were dissolved in 0.1 M PBS with a pH of 7.4, and the concentration was 80 μM.
[0069] In a 5 ml volumetric flask, first add bovine hemoglobin, hemin, pepsin, trypsin, lysozyme, α-chymotrypsin, and γ-globulin at a final concentration of 5 μM, then add the probe at a final concentration of 5 μM, and use 0.1 M PBS buffer to make the mixed solution constant. Let the solution stand for more than 30 minutes. Use an F-7000 fluorescence spectrophotometer to measure the fluorescence emission spectrum of the sample under the conditions of an excitation wavelength of 520 nm, an excitation slit and an emission slit set to 5 nm and 10 nm, respectively.
[0070] like Figure 3 As shown, the probe itself has strong intrinsic fluorescence. After adding bovine hemoglobin to the probe, the probe fluorescence was significantly quenched. However, under the same conditions, pepsin, trypsin, lysozyme, α-chymotrypsin, γ-globulin Example 3 Fluorescent probe hemoglobin response sensitivity test was added to the probe.
[0071] In a 5 ml volumetric flask, first add bovine hemoglobin with a final concentration of 0-7 μM, then add the probe with a final concentration of 5 μM, and use 0.1 M, pH = 7.4 PBS buffer to make the mixed solution constant. Let the solution stand for more than 30 minutes. Use F-7000 fluorescence spectrophotometer to measure the fluorescence emission spectrum of the sample under the conditions of excitation wavelength of 520 nm, excitation slit and emission slit set to 5 nm and 10 nm respectively.
[0072] like Figure 4 As shown in the figure, the intrinsic fluorescence of the probe is significantly quenched as the concentration of bovine hemoglobin increases. When the molar ratio of bovine hemoglobin to probe concentration reaches 1:1, the intrinsic fluorescence of the probe no longer changes. Figure 4As can be seen from the inset, the change in fluorescence intensity (ΔF) of the probe at the emission wavelength of 640 nm showed a good linear correlation (R 2 =0.9988). Based on the signal-to-noise ratio of S / N=3, the detection limit of the probe for bovine hemoglobin was calculated to be 0.26 μM.
[0073] Example 4 Fluorescence quenching test of bovine hemoglobin by fluorescent probe
[0074] In a 5 ml volumetric flask, first add bovine hemoglobin with a final concentration of 5 μM, then add the probe with a final concentration of 0-14 μM, and use 0.1 M, pH = 7.4 PBS buffer to make the mixed solution constant. Let the solution stand for more than 30 minutes. Use F-7000 fluorescence spectrophotometer to measure the fluorescence emission spectrum of the sample under the conditions of excitation wavelength of 280 nm, excitation slit and emission slit set to 5 nm and 5 nm respectively.
[0075] like Figure 5 As shown in Figure 2, the intrinsic fluorescence of bovine hemoglobin was significantly quenched as the probe concentration increased. Figure 5 As can be seen from the inset, the fluorescence intensity of bovine hemoglobin at the emission wavelength of 330 nm showed a good linear correlation with the probe concentration (0-14 μM) within a certain range (R 2 =0.9934). According to the classic Stern-Volmer equation, the association constant between the probe and bovine hemoglobin was calculated to be 6.96×10 4 M -1 .
[0076] Example 5 Experiment on the influence of common commercial drugs on the response ability of fluorescent probe bovine hemoglobin
[0077] Preparation of common commercial drug stock solutions: Ibuprofen, phenylbutazone, ibrutinib, anastrozole, erlotinib, regorafenib, nandrolone, capecitabine, palbociclib, zaltoprofen, lidocaine, moxifloxacin hydrochloride, posaconazole, aripiprazole, repaglinide, trelagliptin, epalrestat, simvastatin, azilsartan, and telaprevir are dissolved in anhydrous ethanol to prepare a stock solution with a concentration of 1 mM.
[0078] In a 5 ml volumetric flask, first add bovine hemoglobin with a final concentration of 5 μM and a probe with a concentration of 5 μM, and then add various commercial drugs with a final concentration of 5 μM (ibuprofen, phenylbutazone, ibrutinib, anastrozole, erlotinib, regorafenib, nandrolone, capecitabine, palbociclib, zaltoprofen, lidocaine, moxifloxacin hydrochloride, posaconazole, aripiprazole, repaglinide, trelagliptin, epalrestat, simvastatin, azilsartan, telaprevir), and use 0.1 M, pH = 7.4 PBS buffer to make the mixed solution constant. Let the solution stand for more than 30 minutes. Use F-7000 fluorescence spectrophotometer, under the conditions of excitation wavelength of 520 nm, excitation slit and emission slit set to 5 nm and 10 nm respectively, to measure the fluorescence emission spectrum of the sample.
[0079] like Figure 6 As shown, except for the classic non-steroidal anti-inflammatory drug ibuprofen, which affects the fluorescence response performance of the probe to bovine hemoglobin, various other commercial drugs (phenylbutazone, ibrutinib, anastrozole, erlotinib, regorafenib, nandrolone, capecitabine, palbociclib, zaltoprofen, lidocaine, moxifloxacin hydrochloride, posaconazole, aripiprazole, repaglinide, trelagliptin, epalrestat, simvastatin, azilsartan, and telaprevir) have no significant effect on the fluorescence response performance of the probe to bovine hemoglobin, indicating that the probe has strong anti-interference ability and is suitable for the accurate and reliable fluorescence response of the probe to hemoglobin in the context of patients receiving multiple types of drug treatment.
[0080] Example 6 Experiment on the effect of ibuprofen on the response ability of fluorescent probe bovine hemoglobin
[0081] In a 5 ml volumetric flask, first add bovine hemoglobin with a final concentration of 5 μM and a probe with a concentration of 5 μM, then add ibuprofen with a final concentration of 0-10 μM, and use 0.1 M PBS, pH = 7.4 to make up the mixed solution. Let the solution stand for more than 30 minutes. Use an F-7000 fluorescence spectrophotometer to measure the fluorescence emission spectrum of the sample under the conditions of an excitation wavelength of 520 nm, an excitation slit and an emission slit set to 5 nm and 10 nm respectively. Figure 7 As shown, with the increase of ibuprofen concentration, the quenched fluorescence of the probe after binding to bovine hemoglobin gradually recovered, indicating that ibuprofen can be used to regulate the fluorescence response of the probe to hemoglobin.
[0082] Example 7 Cytotoxicity Test
[0083] The seeding density in a 6-well plate was 1 × 10 4Different concentrations of probes and complexes of probes and bovine hemoglobin (molar ratio 1:1) were added to the corresponding wells, incubated in a 37°C, 5% CO2 incubator for 24 hours, and then the cytotoxicity of the samples was determined by the MTT method.
[0084] like Figure 8 As shown, as the concentration of the probe and the complex of the probe and bovine hemoglobin (molar ratio 1:1) increased, the liver cancer cell HepG2 maintained extremely high cell activity, indicating that the probe has very low cytotoxicity.
[0085] Example 8 Live Cell Imaging Assay
[0086] HepG2 liver cancer cells were inoculated into laser confocal culture dishes and cultured overnight in a cell culture incubator (37°C, 5% CO2). Three groups were set up in the experiment: the first group only added the probe with a final concentration of 5μM; the second group added a complex of the probe and bovine hemoglobin (molar ratio 1:1) with a final concentration of 5μM; the third group, on the basis of adding a complex of the probe and bovine hemoglobin (molar ratio 1:1) with a final concentration of 5μM, added ibuprofen with a final concentration of 5μM after 1h of culture. Subsequently, each group of cells was cultured for 4h, 12h and 24h respectively under the same cell culture conditions, starting from the time point of probe addition. The culture medium was removed and the cells were washed three times with PBS buffer. The fluorescence imaging effect of the treated HepG2 cells was observed using a laser confocal microscope (excitation wavelength 543nm).
[0087] like Fig. 9 As shown in the figure, the probe has good cell imaging performance in HepG2 cells. However, when the complex of the probe and bovine hemoglobin (molar ratio 1:1) was co-incubated with HepG2 cells for 4 hours, no fluorescence signal was observed in the cells. As the co-incubation time increased, obvious probe fluorescence signals were gradually detected in the cells, which was attributed to the recovery of the probe fluorescence signal during hemoglobin metabolism.
[0088] At the time point of probe addition, the changes in intracellular fluorescence signals before and after the addition of ibuprofen to the complex of probe and bovine hemoglobin (molar ratio 1:1) were compared. The experiment observed that the presence of ibuprofen significantly enhanced the fluorescence signal in the cells. Combined with an in-depth analysis of the effect of ibuprofen on the responsiveness of the fluorescent probe and bovine hemoglobin, it was confirmed that ibuprofen can effectively dissociate the probe from hemoglobin, thereby achieving precise regulation of the hemoglobin fluorescence properties of the probe through ibuprofen.
[0089] In summary, the hemoglobin fluorescent probe of the present invention and its preparation method and use are synthesized based on simple chemical raw materials, have selective hemoglobin quenching response, hemoglobin concentration-dependent response characteristics, and can effectively resist the interference of various common commercial drugs on its response performance. Ibuprofen can be used to achieve precise regulation of the hemoglobin fluorescence performance of the probe. Therefore, the fluorescent probe of the present invention is suitable for accurate detection of hemoglobin in vitro and accurate and controllable fluorescence imaging research mediated by hemoglobin in cells for non-therapeutic or diagnostic purposes.
[0090] Although the embodiments of the present invention have been disclosed above, they are not limited to the applications listed in the specification and the embodiments. It can be fully applied to various fields suitable for the present invention. For those familiar with the art, additional modifications can be easily realized. Therefore, without departing from the general concept defined by the claims and equivalent scope, the present invention is not limited to the specific details and the illustrations shown and described here.
Claims
1. A hemoglobin fluorescent probe, characterized in that: It has the following structural formula:
2. A method for preparing the hemoglobin fluorescent probe according to claim 1, characterized in that: The steps include: Step 1: Add 4-pyridineboronic acid, tetrakis(triphenylphosphine)palladium and K2CO3 to a mixture of 1,4-dioxane and H2O as solvents, then add 4′-(4-bromophenyl)acetophenone, stir and heat under reflux under nitrogen protection; after cooling, separate by column chromatography to obtain 4-(4-pyridyl)-biphenyl-4′-ethanone; The synthesis process of this step is as follows: Step 2: dissolving the 4-(4-pyridyl)-biphenyl-4'-ethanone and malononitrile obtained in step 1 in toluene, adding ammonium acetate and acetic acid, stirring and heating under reflux, cooling and separating by column chromatography to obtain 2-isocyano-3-[4-(4-pyridyl)biphenyl-4'-yl]but-2-enenitrile; The synthesis process of this step is as follows: Step 3: Potassium tert-butoxide and (formylmethylene)triphenylphosphine are stirred in a toluene solvent in an ice bath, added to 6-methoxy-2-naphthaldehyde, heated under reflux under nitrogen protection, cooled, and separated by column chromatography to obtain 3-(6-methoxynaphthalen-2-yl)acrolein; The synthesis process of this step is as follows: Step 4: dissolving the 2-isocyano-3-[4-(4-pyridinyl)biphenyl-4'-yl]but-2-enenitrile obtained in the step, 3-(6-methoxynaphthalen-2-yl)acrolein obtained in step 3 and piperidine in dichloromethane, stirring and heating to reflux, cooling and separating by column chromatography to obtain 2-isocyano-7-(6-methoxynaphthalen-2-yl)-3-[4'-(pyridin-4-yl)biphenyl-4-yl]hept-2,4,6-trienenitrile; The synthesis process of this step is as follows: Step 5: dissolving the 2-isocyano-7-(6-methoxynaphthalen-2-yl)-3-[4'-(pyridin-4-yl)biphenyl-4-yl]hept-2,4,6-trienenitrile and iodomethane obtained in step 4 in acetonitrile, stirring and heating under reflux, cooling and filtering, and eluting with anhydrous ether to obtain the hemoglobin fluorescent probe; The synthesis process of this step is as follows:
3. The method for preparing the hemoglobin fluorescent probe according to claim 2, characterized in that: The specific process of step 1 is: 1.1 Mix 4-pyridineboric acid, tetrakis(triphenylphosphine)palladium and K2CO3 with 1,4-dioxane and H2O, and stir to form a mixed solution; Among them, among them, 1.2 Dissolve 4′-(4-bromophenyl)acetophenone in 1,4-dioxane and mix with the mixed solution in step 1.
1. Protect with nitrogen. Stir the mixed solution at 80°C for 8 hours. Monitor the reaction progress by TLC until the raw material 4′-(4-bromophenyl)acetophenone is completely consumed. 1.3 After the reaction is completed, the mixture is cooled to room temperature, and the reactant is extracted three times with water and dichloromethane. The organic phase is dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude product is purified on a silica gel column to obtain 4-(4-pyridyl)-biphenyl-4'-ethanone; In step 1, the molar ratio of 4-pyridineboric acid, tetrakis(triphenylphosphine)palladium, K2CO3 and 4′-(4-bromophenyl)acetophenone is 3:0.05:6:2; the volume ratio of 1,4-dioxane and H2O is 4:1, wherein the molar volume ratio of tetrakis(triphenylphosphine)palladium to 1,4-dioxane is 3.1-3.2 mmol / L.
4. The method for preparing a hemoglobin fluorescent probe according to claim 2, characterized in that: The specific synthesis process of step 2 is: 4-(4-pyridyl)-biphenyl-4'-ethanone and malononitrile were dissolved in toluene, and then ammonium acetate and acetic acid were added, and the mixture was refluxed for 12 hours. After the reaction was completed by TLC monitoring, the mixture was cooled to room temperature, and extracted with water and dichloromethane. After concentration under reduced pressure, the crude product was purified on a silica gel column to obtain 2-isocyano-3-[4-(4-pyridyl)biphenyl-4'-yl]but-2-enenitrile. In this step, the molar ratio of 4-(4-pyridyl)-biphenyl-4'-ethanone, malononitrile, ammonium acetate and acetic acid is 14:15.4:4.62:13.
02.
5. The method for preparing a hemoglobin fluorescent probe according to claim 2, characterized in that: The specific synthesis process of step 3 is: Potassium tert-butoxide and (formylmethylene)triphenylphosphine were stirred in toluene in an ice bath for 1 to 2 hours, then slowly dripped into 6-methoxy-2-naphthaldehyde and mixed, protected by nitrogen, reacted at 50°C for 24 hours, and after the reaction was completed, quenched with 30% dilute hydrochloric acid, then extracted with water and ethyl acetate, and after the solvent was evaporated, the crude product was purified on a silica gel column to obtain 3-(6-methoxynaphthalen-2-yl)propenal; In this step, the molar ratio of 6-methoxy-2-naphthaldehyde, potassium tert-butoxide, and (formylmethylene)triphenylphosphine is 3:6:3.
3.
6. The method for preparing a hemoglobin fluorescent probe according to claim 2, characterized in that: The specific synthesis process of step 4 is: 2-isocyano-3-[4-(4-pyridinyl)biphenyl-4'-yl]but-2-enenitrile and 3-(6-methoxynaphthalen-2-yl)acrolein in a molar ratio of 0.9:1 were mixed, dissolved in dichloromethane with piperidine, and refluxed for 6 to 8 hours. After concentration under reduced pressure, the crude product was purified on a silica gel column to obtain 2-isocyano-7-(6-methoxynaphthalen-2-yl)-3-[4'-(pyridin-4-yl)biphenyl-4-yl]hept-2,4,6-trienenitrile.
7. The method for preparing a hemoglobin fluorescent probe according to claim 2, characterized in that: 2-Isocyano-7-(6-methoxynaphthalen-2-yl)-3-[4'-(pyridin-4-yl)biphenyl-4-yl]hept-2,4,6-trienenitrile and iodomethane 1 in a molar ratio of 0.43:1.3 were dissolved in acetonitrile and refluxed for 24 hours. After concentration under reduced pressure, acetonitrile was added until dissolved, precipitated with ether, filtered and washed to obtain the target hemoglobin fluorescent probe.
8. The method for preparing a hemoglobin fluorescent probe according to claim 3, 4 or 5, characterized in that: The silica gel column is a mixture of ethyl acetate and dichloromethane in a volume ratio of 1:
2.
9. Use of the hemoglobin fluorescent probe according to claim 1 in hemoglobin detection or hemoglobin-mediated intracellular controllable fluorescence imaging.
Citation Information
Patent Citations
Near-infrared fluorescent probe for detecting human serum albumin as well as preparation method and application of near-infrared fluorescent probe
CN118290413A
Method for evaluating the structural and functional properties of blood plasma albumin
WO2013125932A1
Cited By
Beta-lactoglobulin fluorescent probe as well as preparation method and application thereof
CN120118029A
